W
William J. Greenlee
Researcher at Merck & Co.
Publications - 330
Citations - 10575
William J. Greenlee is an academic researcher from Merck & Co.. The author has contributed to research in topics: Angiotensin II & Angiotensin II receptor type 1. The author has an hindex of 52, co-authored 326 publications receiving 10272 citations. Previous affiliations of William J. Greenlee include Schering-Plough & United States Military Academy.
Papers
More filters
Journal ArticleDOI
A new class of angiotensin-converting enzyme inhibitors
Arthur A. Patchett,Elbert E. Harris,Tristram Edward W,Matthew J. Wyvratt,Mu Tsu Wu,David Taub,E. R. Peterson,T.J. Ikeler,ten Broeke J,L.G. Payne,D. L. Ondeyka,Eugene D. Thorsett,William J. Greenlee,Nancy S. Lohr,Hoffsommer Rd,Henry Joshua,William V Ruyle,John W. Rothrock,Aster Sd,Alan L. Maycock,Robinson Fm,Hirschmann Ralph F,C. S. Sweet,E. H. Ulm,Dennis M. Gross,T. C. Vassil,Stone Ca +26 more
TL;DR: This work reports on the design of a novel series of substituted N-carboxymethyl-dipeptides which are active in inhibiting angiotensin-converting enzyme at nanomolar levels and suggests that these compounds are transition-state inhibitors.
Journal ArticleDOI
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.
Julie M. Strizki,Serena Xu,Nicole Wagner,Lisa Wojcik,Jia Liu,Yan Hou,Matthias Endres,Anandan Palani,Sherry Shapiro,John W. Clader,William J. Greenlee,Jayaram R. Tagat,Stuart W. McCombie,Kathleen Cox,Ahmad Fawzi,Chuan-Chu Chou,Catherine Pugliese-Sivo,Liza Davies,Mary E. Moreno,David D. Ho,Alexandra Trkola,Cheryl A. Stoddart,John P. Moore,Gregory R. Reyes,Bahige M. Baroudy +24 more
TL;DR: SCH-C has broad and potent antiviral activity in vitro against primary HIV-1 isolates that use CCR5 as their entry coreceptor, with mean 50% inhibitory concentrations ranging between 0.4 and 9 nM.
Journal ArticleDOI
Nonpeptide Angiotensin II Receptor Antagonists: The Next Generation in Antihypertensive Therapy
Ruth R. Wexler,William J. Greenlee,John D. Irvin,Michael Goldberg,Kristine Prendergast,Ronald D. Smith,Pieter B.M.W.M. Timmermans +6 more
Journal ArticleDOI
Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.
Samuel Chackalamannil,Yuguang Wang,William J. Greenlee,Zhiyong Hu,Yan Xia,Ho-Sam Ahn,George Boykow,Yunsheng Hsieh,Jairam Palamanda,Jacqueline Agans-Fantuzzi,Stan Kurowski,Michael P. Graziano,Madhu Chintala +12 more
TL;DR: 4 (SCH 530348), a potent, oral antiplatelet agent that is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.
Patent
Substituted imidazo-fused 6-membered heterocycles as angiotensin ii antagonists
Prasun K. Chakravarty,William J. Greenlee,Nathan B. Mantlo,Arthur A. Patchett,Thomas F. Walsh +4 more
TL;DR: Substituted Imidazo-fused 6-membered heterocycles of structural formula are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure as mentioned in this paper.